Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
News and updates for Alterity Therapeutics Limited (ATHE) center on its progress as a clinical stage biotechnology company developing disease modifying treatments for neurodegenerative diseases. The company’s announcements emphasize its initial focus on Parkinson’s disease and related disorders, particularly Multiple System Atrophy (MSA), and the development of its lead oral agent ATH434.
Investors and followers of ATHE can expect regular news about clinical trial milestones and data presentations. Alterity has reported positive results from its ATH434‑201 randomized, double‑blind, placebo‑controlled Phase 2 trial in MSA, as well as topline data from the ATH434‑202 open‑label Phase 2 trial in more advanced MSA. Company news often highlights analyses of UMSARS Part I activities of daily living scores, orthostatic hypotension symptom assessments, wearable sensor data, and neuroimaging and biomarker endpoints such as brain iron and the MSA Atrophy Index.
Alterity’s news flow also includes regulatory and designation updates, such as Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the FDA and European Commission for ATH434 in MSA. Additional items cover participation in major neurology and movement disorder conferences, where the company presents new analyses, biomarker findings, and natural history study results, as well as appearances at healthcare and biotech investor events.
On this page, readers can follow announcements about capital raises, quarterly cash flow reports, and corporate presentations that describe Alterity’s cash position, development plans, and engagement with regulators. For those tracking ATHE, the news stream provides context on how the company is advancing ATH434 in MSA, refining its biomarker strategy, and interacting with the scientific and investment communities over time.
Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) released its Appendix 4C and a corporate update for Q3 FY26. Key items: FDA Type C feedback aligned on clinical pharmacology, non-clinical and CMC elements for a planned Phase 3 in MSA, with an End-of-Phase 2 meeting on track for mid-2026.
New Phase 2 analyses using the MuSyCA endpoint showed a treatment effect of −1.9 (75 mg) to −4.0 points (50 mg, p=0.034; relative effect 41%) at Week 52. Cash A$44.53M as of 31 March 2026; operating outflow A$4.73M for the quarter.
Alterity Therapeutics (NASDAQ: ATHE) received positive FDA feedback after a second Type C meeting on its planned ATH434 Phase 3 program in Multiple System Atrophy (MSA). The FDA provided written support for the program's chemistry, manufacturing, and control (CMC) elements, and manufacturing scale-up is progressing.
An End-of-Phase 2 meeting remains on track for mid-2026, moving the company closer to Phase 3 initiation while clinical pharmacology and non-clinical topics were addressed in an earlier Type C meeting.
Alterity Therapeutics (NASDAQ: ATHE) presented new analyses from the ATH434 Phase 2 MSA trial at AAN on April 22, 2026, showing ATH434 slowed functional decline versus placebo on a novel MuSyCA composite scale and on modified UMSARS Part I.
MuSyCA showed placebo worsening ~+9.7 points at Week 52; ATH434 treatment effects ranged from −1.9 (75 mg) to −4.0 points (50 mg, p=0.034). Modified UMSARS I effects were −3.1 (75 mg) and −4.7 points (50 mg, p=0.029). Data support ATH434's clinical profile ahead of Phase 3 regulator engagement.
Alterity Therapeutics (NASDAQ: ATHE) appointed Ann Cunningham as an independent Non-Executive Director effective 17 April 2026. The appointment adds >25 years of global pharmaceutical and biotech commercial experience as Alterity prepares to advance ATH434 into Phase 3 development for Multiple System Atrophy (MSA).
Ms Cunningham’s background includes senior commercial roles at Lilly and Teva, founder/CEO of i³ Strategy Partners, prior leadership on product launches including Cymbalta and Rexulti, and a board role at Vistagen Therapeutics.
Alterity Therapeutics (NASDAQ: ATHE) announced a Late-Breaker oral presentation at the American Academy of Neurology Annual Meeting on April 21, 2026, highlighting positive clinical signals for ATH434 in Multiple System Atrophy (MSA) using the MuSyCA composite scale.
The company reported clinically meaningful efficacy in a randomized Phase 2 trial, positive open-label data in advanced MSA, and said it is preparing to initiate a Phase 3 pivotal trial.
Alterity Therapeutics (NASDAQ: ATHE) will host a virtual KOL event on April 28, 2026 (US) and April 29, 2026 (Australia) to share new insights on ATH434 for Multiple System Atrophy (MSA). The session will review Phase 2 data and provide a high-level Phase 3 planning overview.
Alterity Therapeutics (NASDAQ: ATHE) received positive feedback from a Type C meeting with the FDA on March 30, 2026, supporting its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).
The FDA provided written support for the company’s clinical pharmacology and non-clinical development elements. Alterity said it will seek agreement on CMC and the Phase 3 trial design, with an End-of-Phase 2 meeting on track for mid-year 2026.
Alterity Therapeutics (NASDAQ: ATHE) announced that CEO Dr. David Stamler will participate in the Bell Potter Healthcare Horizons Summit on 12-13 March 2026 in Sorrento, Australia.
Dr. Stamler will join a fireside chat titled “Optimising Late-stage Clinical Trials to Increase the Odds” and will hold 1-on-1 investor meetings.
Alterity Therapeutics (NASDAQ: ATHE) appointed Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor effective March 2026. Dr. Claassen retains his Vanderbilt University Medical Center professorship and brings >20 years in movement disorders and neurodegenerative clinical research.
His prior role as coordinating investigator on the ATH434 Phase 2 study and experience as a principal investigator are cited as key qualifications to help advance ATH434 into Phase 3 for multiple system atrophy (MSA).
Alterity Therapeutics (NASDAQ: ATHE) recognizes Multiple System Atrophy Awareness Month and highlights its investigational oral therapy ATH434, advanced in clinical development for MSA. The company reported Phase 2 data showing meaningful clinical benefit with favorable safety and tolerability, and uses biomarkers and neuroimaging to assess impact.
Alterity will share educational content and support advocacy during March while continuing ATH434 development aimed at disease-modifying approaches for this rapidly progressive, currently untreatable disorder.